1-16 of 16
Ian Judson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract B28: The accuracy of tissue microarrays in the study of the sarcoma immune microenvironment is dependent on the number of sampled cores

Alex Lee, Khin Thway, Seth Pollack, Ian Judson, Paul Huang, Robin Jones
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (2_Supplement): B28.
https://doi.org/10.1158/1557-3265.SARCOMAS17-B28
Published: 15 January 2018
View article titled, Abstract B28: The accuracy of tissue microarrays in the study of the sarcoma immune microenvironment is dependent on the number of sampled cores
Journal Articles

DNA repair efficiency as a model for personalized therapy with Trabectedin

Rafael Rosell, Federica Grosso, Patrick Schoffski, Paolo Casali, Robert Maki, Miquel Taron, Pedro Mendez, Imane Chaib, Antonio Nieto, Juan Carlos Tercero, Robin Jones, Ian Judson, Jean-Yves Blay, Axel Lecesne, Jose Jimeno
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (19_Supplement): A57.
Published: 15 August 2014
View article titled, DNA repair efficiency as a model for personalized therapy with Trabectedin
Journal Articles

Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma

Ian Judson, Michelle Scurr, Kate Gardner, Elizabeth Barquin, Marcelo Marotti, Barbara Collins, Helen Young, Juliane M. Jürgensmeier, Michael Leahy
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (13): 3603–3612.
https://doi.org/10.1158/1078-0432.CCR-13-1881
Published: 30 June 2014
View article titled, Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma
Open the PDF for Phase II Study of Cediranib in Patients with Advanced Gastrointestinal Stromal Tumors or Soft-Tissue Sarcoma in another window
Includes: Supplementary data
Journal Articles

Therapeutic Drug Monitoring of Imatinib—New Data Strengthen the Case

Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (20): 5517–5519.
https://doi.org/10.1158/1078-0432.CCR-12-2570
Published: 14 October 2012
View article titled, Therapeutic Drug Monitoring of Imatinib—New Data Strengthen the Case
Open the PDF for Therapeutic Drug Monitoring of Imatinib—New Data Strengthen the Case in another window
Includes: Supplementary data
Journal Articles

Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era

Philippe A. Cassier, Elena Fumagalli, Piotr Rutkowski, Patrick Schöffski, Martine Van Glabbeke, Maria Debiec-Rychter, Jean-François Emile, Florence Duffaud, Javier Martin-Broto, Bruno Landi, Antoine Adenis, François Bertucci, Emmanuelle Bompas, Olivier Bouché, Serge Leyvraz, Ian Judson, Jaap Verweij, Paolo Casali, Jean-Yves Blay, Peter Hohenberger, for the European Organisation for Research and Treatment of Cancer
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (16): 4458–4464.
https://doi.org/10.1158/1078-0432.CCR-11-3025
Published: 14 August 2012
View article titled, Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era
Open the PDF for Outcome of Patients with Platelet-Derived Growth Factor Receptor Alpha–Mutated Gastrointestinal Stromal Tumors in the Tyrosine Kinase Inhibitor Era in another window
Includes: Supplementary data
Journal Articles

Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer

Paul Nathan, Martin Zweifel, Anwar R. Padhani, Dow-Mu Koh, Matthew Ng, David J. Collins, Adrian Harris, Craig Carden, Jon Smythe, Nita Fisher, N. Jane Taylor, J. James Stirling, Shiao-Ping Lu, Martin O. Leach, Gordon J.S. Rustin, Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (12): 3428–3439.
https://doi.org/10.1158/1078-0432.CCR-11-3376
Published: 14 June 2012
View article titled, Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
Open the PDF for Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer in another window
Journal Articles

A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

Simon Pacey, Richard H. Wilson, Mike Walton, Martin M. Eatock, Anthea Hardcastle, Anna Zetterlund, Hendrik-Tobias Arkenau, Javier Moreno-Farre, Udai Banerji, Belle Roels, Heidi Peachey, Wynne Aherne, Johan S. de Bono, Florence Raynaud, Paul Workman, Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (6): 1561–1570.
https://doi.org/10.1158/1078-0432.CCR-10-1927
Published: 15 March 2011
View article titled, A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors

Ruth Plummer, Laura Vidal, Melanie Griffin, Mark Lesley, Johann de Bono, Sally Coulthard, Julieann Sludden, Lillian L. Siu, Eric X. Chen, Amit M. Oza, Gregory K. Reid, A. Robert McLeod, Jeffrey M. Besterman, Chooi Lee, Ian Judson, Hilary Calvert, Alan V. Boddy
Journal: Clinical Cancer Research
Clin Cancer Res (2009) 15 (9): 3177–3183.
https://doi.org/10.1158/1078-0432.CCR-08-2859
Published: 30 April 2009
View article titled, Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors
Open the PDF for Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors in another window
Journal Articles

Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC

Nielka van Erp, Hans Gelderblom, Martine van Glabbeke, Allan Van Oosterom, Jaap Verweij, Henk-Jan Guchelaar, Maria Debiec-Rychter, Bin Peng, Jean-Yves Blay, Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (24): 8308–8313.
https://doi.org/10.1158/1078-0432.CCR-08-1303
Published: 15 December 2008
View article titled, Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC
Open the PDF for Effect of Cigarette Smoking on Imatinib in Patients in the Soft Tissue and Bone Sarcoma Group of the EORTC in another window
Journal Articles

Biomarkers In Early Clinical Trials: the Committed and the Skeptics

Udai Banerji, Johann de Bono, Ian Judson, Stanley Kaye, Paul Workman
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (8): 2512.
https://doi.org/10.1158/1078-0432.CCR-07-5224
Published: 15 April 2008
View article titled, Biomarkers In Early Clinical Trials: the Committed and the Skeptics
Open the PDF for Biomarkers In Early Clinical Trials: the Committed and the Skeptics in another window
Journal Articles

Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers

Ruth Plummer, Gerhardt Attard, Simon Pacey, Louise Li, Albiruni Razak, Rebecca Perrett, Mary Barrett, Ian Judson, Stan Kaye, Norma Lynn Fox, Wendy Halpern, Alfred Corey, Hilary Calvert, Johann de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (20): 6187–6194.
https://doi.org/10.1158/1078-0432.CCR-07-0950
Published: 18 October 2007
View article titled, Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers
Open the PDF for Phase 1 and Pharmacokinetic Study of Lexatumumab in Patients with Advanced Cancers in another window
Journal Articles

HDAC Inhibitors and Cardiac Safety

Rhoda Molife, Peter Fong, Michelle Scurr, Ian Judson, Stan Kaye, Johann de Bono
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (3): 1068.
https://doi.org/10.1158/1078-0432.CCR-06-1715
Published: 08 February 2007
View article titled, HDAC Inhibitors and Cardiac Safety
Open the PDF for HDAC Inhibitors and Cardiac Safety in another window
Journal Articles

Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models

Udai Banerji, Michael Walton, Florence Raynaud, Rachel Grimshaw, Lloyd Kelland, Melani Valenti, Ian Judson, Paul Workman
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (19): 7023–7032.
https://doi.org/10.1158/1078-0432.CCR-05-0518
Published: 03 October 2005
View article titled, Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models
Open the PDF for Pharmacokinetic-Pharmacodynamic Relationships for the Heat Shock Protein 90 Molecular Chaperone Inhibitor 17-Allylamino, 17-Demethoxygeldanamycin in Human Ovarian Cancer Xenograft Models in another window
Includes: Supplementary data
Journal Articles

A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy

Beatrice M. Seddon, Geoffrey S. Payne, Laura Simmons, Ruth Ruddle, Rachel Grimshaw, Siew Tan, Alison Turner, Florence Raynaud, Gavin Halbert, Martin O. Leach, Ian Judson, Paul Workman
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (14): 5101–5112.
Published: 12 November 2003
View article titled, A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy
Open the PDF for A Phase I Study of SR-4554 via Intravenous Administration for Noninvasive Investigation of Tumor Hypoxia by Magnetic Resonance Spectroscopy in Patients with Malignancy in another window
Journal Articles

Phase I Trial of ZD9331, a Nonpolyglutamatable Thymidylate Synthase Inhibitor, Given as a 5-Day Continuous Infusion to Patients with Refractory Solid Malignancies

Charlotte Rees, P. Beale, Jose Manuel Trigo, Fraser Mitchell, Anne Jackman, Robert Smith, Edwin Douglass, Ian Judson
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (6): 2049–2055.
Published: 01 June 2003
View article titled, Phase I Trial of ZD9331, a Nonpolyglutamatable Thymidylate Synthase Inhibitor, Given as a 5-Day Continuous Infusion to Patients with Refractory Solid Malignancies
Open the PDF for Phase I Trial of ZD9331, a Nonpolyglutamatable Thymidylate Synthase Inhibitor, Given as a 5-Day Continuous Infusion to Patients with Refractory Solid Malignancies in another window
Journal Articles

A Phase I Trial of ZD9331, a Water-Soluble, Nonpolyglutamatable, Thymidylate Synthase Inhibitor

Ruth Plummer, Charlotte Rees, Andrew Hughes, Philip Beale, Martin Highley, Jose Trigo, Sathyarathnarn Gokul, Ian Judson, Hilary Calvert, Ann Jackman, Fraser Mitchell, Robert Smith, Edwin Douglass
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (4): 1313–1322.
Published: 01 April 2003
View article titled, A Phase I Trial of ZD9331, a Water-Soluble, Nonpolyglutamatable, Thymidylate Synthase Inhibitor
Open the PDF for A Phase I Trial of ZD9331, a Water-Soluble, Nonpolyglutamatable, Thymidylate Synthase Inhibitor in another window